C07D 217/16
Substituted by oxygen atoms
Official title: substituted by oxygen atoms
C07D217/16 (Substituted by oxygen atoms) appears on 333 US grants and 285 published applications in this corpus.
Search patents in C07D- Granted patents
- 333
- Published applications
- 285
- Assignees
- 194
- Inventors
- 1,095
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 5 | 0 |
| 1978 | 5 | 0 |
| 1979 | 3 | 0 |
| 1980 | 2 | 0 |
| 1981 | 5 | 0 |
| 1982 | 6 | 0 |
| 1983 | 5 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 2 | 0 |
| 1987 | 4 | 0 |
| 1988 | 4 | 0 |
| 1989 | 2 | 0 |
| 1990 | 5 | 0 |
| 1991 | 3 | 0 |
| 1992 | 5 | 0 |
| 1993 | 6 | 0 |
| 1994 | 2 | 0 |
| 1995 | 6 | 0 |
| 1996 | 6 | 0 |
| 1997 | 11 | 0 |
| 1998 | 10 | 0 |
| 1999 | 8 | 0 |
| 2000 | 7 | 0 |
| 2001 | 4 | 1 |
| 2002 | 5 | 4 |
| 2003 | 3 | 5 |
| 2004 | 3 | 14 |
| 2005 | 5 | 19 |
| 2006 | 3 | 15 |
| 2007 | 10 | 8 |
| 2008 | 5 | 9 |
| 2009 | 10 | 19 |
| 2010 | 11 | 19 |
| 2011 | 11 | 8 |
| 2012 | 19 | 13 |
| 2013 | 19 | 12 |
| 2014 | 13 | 26 |
| 2015 | 21 | 13 |
| 2016 | 14 | 14 |
| 2017 | 10 | 9 |
| 2018 | 7 | 8 |
| 2019 | 12 | 10 |
| 2020 | 7 | 7 |
| 2021 | 3 | 11 |
| 2022 | 6 | 6 |
| 2023 | 1 | 11 |
| 2024 | 6 | 11 |
| 2025 | 6 | 7 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists22 Sep 2026US 12,741,957 B2Takeda Pharmaceutical Company Limited
- Inhibitors of MLH1 and/or PMS2 for cancer treatment17 Feb 2026US 12,552,758 B2NeoPhore Limited
- Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators23 Dec 2025US 12,503,442 B2Eli Lilly and Company
- Synthesis of deuterated aldehydes28 Oct 2025US 12,454,502 B2Arizona Board of Regents On Behalf of Athe University of Arizona
- 6-methoxy-3,4-dihydro-1H-isoquinolin compounds28 Oct 2025US 12,454,511 B2Eli Lilly and Company
- Methods of producing morphinan alkaloids and derivatives27 Aug 2026US 2026/0250729 A1Antheia, Inc.
- Tetrahydroisoquinolinylmethylbenzamide compounds19 Feb 2026US 2026/0049060 A1National Health Research Institutes
- Amino acid active ester and salt thereof15 Jan 2026US 2026/0015313 A1
- Chemical compounds and uses thereof15 Jan 2026US 2026/0015321 A1Glaxosmithkline Intellectual Property (No. 4) Ltd.
- Quinolinone amide compounds and uses thereof8 Jan 2026US 2026/0008774 A1Edgewise Therapeutics, Inc.
Most cited
By later US patents
- Retroviral protease inhibiting compounds159US 5,142,056 AAbbott Laboratories · 1992
- Anti-estrogenic compounds and compositions119US 5,395,842 AEndorecherche, Inc. · 1995
- Retroviral protease inhibiting compounds109US 5,354,866 AAbbott Laboratories · 1994
- 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis98US 5,552,412 APfizer Inc. · 1996
- Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases71US 8,563,735 B2AbbVie Inc. · 2013